ALMKT:EPA
Mauna Kea Technologies SA
0,092 €
0,00%
(0,00) 1D
13 ნოე, 17:35:01 GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALMKT...
Mkt. cap
18,11 მლნ.
Avg. vol.
484,45 ათ.
Volume
0,00
P/E ratio
0,79
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 მლნ.
No. of employees
56
Mkt. cap
18,11 მლნ.
Avg. vol.
484,45 ათ.
Volume
0,00
P/E ratio
0,79
52-wk high
0,23 €
52-wk low
0,07 €
EPS
0,12 €
Shares outstanding
195,26 მლნ.
No. of employees
56
News stories
From web sources and news partners
Investing.com
·
50 წუთის წინ
Bulls See S&P 500 Hitting 7,900 by Year-End as Earnings and Valuations Improve
The Motley Fool
·
53 წუთის წინ
The S&P 500 Looks Cheaper Than It Has in Over 3 Years, but There’s a Catch
Benzinga
·
1 საათის წინ
Stock Market: Will S&P 500 Open Up or Down Today?
StoneX
·
3 დღის წინ
S&P 500, Nasdaq 100 Claw Back But NVDA Cloud Looms Overhead
Profile
Mauna Kea Technologies is a global medical device company focused on endomicroscopy, the field of microscopic imaging during endoscopy procedures. The company researches, develops and markets tools to visualize, detect, and rule out abnormalities including malignant and pre-malignant tumors or lesions in the gastrointestinal and pulmonary tracts.
The company makes Cellvizio, a probe-based Confocal Laser Endomicroscopy system, which provides physicians and researchers with real-time access to histological information during standard endoscopy procedures through high-resolution cellular imaging of internal tissues.
Cellvizio is used in medical applications such as gastrointestinal endoscopy, pulmonology and urology to help physicians diagnose lesions and make accurate treatment decisions in real-time.
Cellvizio went public in July 2011 and trades on the Euronext Paris exchange. Wikipedia
About Mauna Kea Technologies SA
CEOსაჩა ლოისო
Employees56
Founded2000
Headquarters-
SectorHealth Care
IndustryMedical device
Websitemaunakeatech.com